HATFIELD, England, December 6, 2013 /PRNewswire/ --
Eisai today announced that 16 abstracts highlighting new data analyses on Fycompa(R) (perampanel) will be presented at the 67th annual American Epilepsy Society (AES) meeting in Washington, D.C. between 6-10 December. Perampanel is indicated in the European Union (EU) for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.[1]
"These data analyses highlight Eisai's clinical research with Fycompa and reinforce our commitment to the epilepsy community," commented Lynn Kramer, MD, President of the Neuroscience and General Medicine Product Creation Unit and Chief Clinical Officer of Eisai Product Creation Systems, Eisai's research and development organisation.
The following abstracts regarding perampanel will be presented at this year's AES Meeting:
Abstract Number Abstract Name
Assessment of Liver Toxicity in Perampanel-Treated
1.140 Subjects: Pooled Results From Phase III Clinical Trials
Poster Session Antonio Laurenza, Haichen Yang, Betsy Williams, Sharon
1 Zhou, Jim Ferry
Lack of Effect of Perampanel on QT Interval Duration:
Results From a Thorough QT Analysis and Pooled Phase III
Clinical Trials
1.141
Haichen Yang, Antonio Laurenza, Betsy Williams, Anna
Poster Session Patten, Ziad Hussein, Jim Ferry
1 Efficacy and Safety of Perampanel in the Subgroup of
Elderly Patients Included in the Phase III Epilepsy
1.142 Clinical Trials
Poster Session Betsy Williams, Robert Wechsler, Antonio Laurenza, Haichen
1 Yang, Sharon Zhou, Ilo Leppik
Pharmacokinetics of Perampanel: Results From Phase I
1.143 Clinical Pharmacology Studies
Poster Session Barry E. Gidal, Antonio Laurenza, Haichen Yang, Betsy
1 Williams, David A. Verbel, Jim Ferry
GABA vs. Non-GABA Mechanism of Action of Concomitant
Antiepileptic Drugs: Post-hoc Analysis of Pooled
1.144 Perampanel Phase III Studies
Poster Session Mare Muller, Haichen Yang, Betsy Williams, Tony Ma,
1 Antonio Laurenza, Steve Chung
Subgroup Analysis by Gender in Perampanel Phase III
1.145 Studies of Patients Diagnosed With Partial-Onset Seizures
Poster Session Blanca Vazquez, Haichen Yang, Betsy Williams, Sharon Zhou,
1 Antonio Laurenza
Review of Psychiatric and Behavioral Events in Perampanel
1.146 Clinical Studies
Poster Session Alan B. Ettinger, Antonia LoPresti, Haichen Yang, Betsy
1 Williams, Sharon Zhou, Randi Fain, Antonio Laurenza
Pooled Perampanel Phase III Trials: Time to Onset and
1.147 Duration for Most Common Adverse Events
Poster Session David Ko, Haichen Yang, Betsy Williams, Dongyuan Xing,
1 Antonio Laurenza
1.154 Evaluation of Abuse Potential of Perampanel
Poster Session Jim Ferry, Haichen Yang, Betsy Williams, Kate Bradshaw,
1 Reginald V. Fant, Antonio Laurenza
Efficacy and Safety of Adjunct Perampanel Based on Number
of Antiepileptic Drugs at Baseline and Baseline Predictors
1.230 of Efficacy: Phase III Post-Hoc Analysis
Poster Session Tracy Glauser, Antonio Laurenza, Haichen Yang, Betsy
1 Williams, Dongyuan Xing, Randi Fain
Lesional vs. Non-lesional Partial Epilepsy: Post-hoc
2.048 Analysis of Pooled Perampanel Phase III Studies
Poster Session Stephanie Marsh, Haichen Yang, Betsy Williams, Steve
2 Huang, Antonio Laurenza, Steve Chung
Efficacy and Safety of Perampanel in Patients With
Neurologic & Psychiatric Comorbidities: Post-hoc Analysis
2.049 of Phase III Epilepsy Trials
Poster Session David Squillacote, Haichen Yang, Betsy Williams, Sharon
2 Zhou, Antonio Laurenza, Victor Biton
Analysis of Aggression in Perampanel Phase III Epilepsy
2.050 Clinical Trials
Poster Session Antonia LoPresti, Alan B. Ettinger, Haichen Yang, Betsy
2 Williams, Sharon Zhou, Randi Fain, Antonio Laurenza
Effect of Ketoconazole on Perampanel Pharmacokinetics
2.063
Rama Maganti, Antonio Laurenza, Haichen Yang, Betsy
Poster Session Williams, David A. Verbel, Edgar Schuck, Jim Ferry, Barry
2 E. Gidal
Exploration of Adverse Events by Region, and Detailed
Focus on Psychiatric Events, With Long-term Open-label
Perampanel Treatment
2.148
Elinor Ben-Menachem, Gregory Krauss,
Poster Session
2 Michelle Gee, Makarand Bagul, Dinesh Kumar
Long-term Retention, and Reasons for Discontinuations,
With Perampanel Treatment in Pharmacoresistant Focal
3.211 Seizures
Poster Session Jerry Shih, Emilio Perucca, Michelle Gee, Makarand Bagul,
3 Dinesh Kumar
The on-going research into perampanel underscores Eisai's human health care (hhc) mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and wellbeing of people worldwide.
Notes to Editors
About Perampanel
Perampanel is licensed in the European Union (EU) for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.[1]
Perampanel is a highly selective, non-competitive AMPA ( alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptor antagonist that has demonstrated seizure reduction in Phase II and III studies. AMPA receptors, widely present in almost all excitatory neurons, transmit signals stimulated by the excitatory neurotransmitter glutamate within the brain and are believed to play a role in central nervous system diseases characterised by excess neuroexcitatory signalling including epilepsy.[1]
Further information for healthcare professionals can be found at http://www.fycompa.eu
About Epilepsy
Epilepsy is one of the most common neurological conditions in the world, affecting approximately eight in 1,000 people in Europe, and an estimated 50 million people worldwide.[2],[3] Epilepsy is a chronic disorder of the brain that affects people of all ages. It is characterised by abnormal discharges of neuronal activity causing seizures. Seizures can vary in severity, from brief lapses of attention or jerking of muscles, to severe and prolonged convulsions. Depending on the seizure type, seizures may be limited to one part of the body, or may involve the whole body. Seizures can also vary in frequency from less than one per year, to several per day. Epilepsy has many possible causes but often the cause is unknown.
About Eisai EMEA in Epilepsy
(CONTINUA)
Andalucía
